EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Impact of Helicobacter pylori on Immune Checkpoint Inhibition in Hepatocellular Carcinoma: A Multicenter Study

Najib Ben Khaled, Christian Schulz, Marianna Alunni-Fabbroni, Kathrin Bronny, Leonie S Jochheim, Behnam Kalali, Osman Öcal, Max Seidensticker, Ignazio Piseddu, Stefan Enssle, Monika Karin, Julia S Schneider und 11 weitere

Digestion · 2025

DOI: 10.1159/000542847 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Digestion, 2025. Verfasst von Najib Ben Khaled und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine II, University Hospital, LMU Munich, Munich, Germany, najib.benkhaled@med.uni-muenchen.de. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Hepatocellular, Helicobacter Infections, Helicobacter pylori. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Immunomodulating effects of Helicobacter pylori (H. pylori) have been shown to inhibit antitumor immunity. Resistance to immune checkpoint inhibitor (ICI)-based therapies is common among patients with hepatocellular carcinoma (HCC). This study aimed to assess the effect of H. pylori on the outcomes of ICI in patients with HCC.

Methods

We conducted a multicenter study in patients with HCC across a broad range of treatments. Patients received either ICI-based combination regimens or sorafenib-based therapy. H. pylori serostatus and virulence factors were determined and correlated with overall survival (OS), progression-free survival (PFS), and safety across the treatment modalities.

Results

180 patients with HCC were included; among these, 64 were treated with ICI-based regimen and 116 with sorafenib-based regimen. In patients treated with ICI, median OS was shorter in H. pylori-positive patients (10.9 months in H. pylori-positive vs. 18.3 months; p = 0.0384). H. pylori positivity was associated with a shorter PFS in ICI recipients (3.9 months vs. 6.8 months, p = 0.0499). In patients treated with sorafenib, median OS was not shorter among H. pylori-positive patients (13.4 months in H. pylori-positive vs. 10.6 months; p = 0.3353). Immune-related adverse events and rates of gastrointestinal bleeding were comparable between H. pylori-positive and -negative patients.

Conclusion

H. pylori seropositivity was linked to poorer outcomes in patients with HCC treated with ICI. This association was not observed among patients receiving sorafenib-based therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularHelicobacter InfectionsHelicobacter pyloriImmune Checkpoint InhibitorsLiver NeoplasmsAgedFemaleHumansMaleMiddle AgedDrug Resistance, NeoplasmProgression-Free SurvivalRetrospective StudiesSorafenibTreatment Outcome

Stichwörter der Autor:innen

Helicobacter pyloriHepatocellular carcinomaImmune checkpoint inhibitorImmunotherapyResistance

Substanzen

Immune Checkpoint InhibitorsSorafenib

Autor:innen und Institutionen

  • Department of Medicine II, University Hospital, LMU Munich, Munich, Germany, najib.benkhaled@med.uni-muenchen.de.
  • German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany, najib.benkhaled@med.uni-muenchen.de.
  • Bavarian Cancer Research Center (BZKF), Erlangen, Germany, najib.benkhaled@med.uni-muenchen.de.
  • Department of Medicine II, University Hospital, LMU Munich, Munich, Germany.
  • Munich Partner Site, German Center for Infection Research (DZIF), Munich, Germany.
  • Department of Radiology, University Hospital, LMU Munich, Munich, Germany.

Zitieren

APA

Ben Khaled, N., Schulz, C., Alunni-Fabbroni, M., Bronny, K., Jochheim, L. S., Kalali, B., Öcal, O., Seidensticker, M., Piseddu, I., Enssle, S., Karin, M., Schneider, J. S., Strasoldo-Graffemberg, T., Koch, N., Macke, L., Reiter, F. P., Lange, C. M., Wang, Y., De Toni, E. N., …, & Malfertheiner, P. (2025). Impact of Helicobacter pylori on Immune Checkpoint Inhibition in Hepatocellular Carcinoma: A Multicenter Study. Digestion. https://doi.org/10.1159/000542847

Vancouver

Ben Khaled N, Schulz C, Alunni-Fabbroni M, Bronny K, Jochheim LS, Kalali B, et al. Impact of Helicobacter pylori on Immune Checkpoint Inhibition in Hepatocellular Carcinoma: A Multicenter Study. Digestion. 2025. doi:10.1159/000542847

BibTeX
@article{BenKhaled2025,
  author = {Ben Khaled, Najib and Schulz, Christian and Alunni-Fabbroni, Marianna and Bronny, Kathrin and Jochheim, Leonie S and Kalali, Behnam and Öcal, Osman and Seidensticker, Max and Piseddu, Ignazio and Enssle, Stefan and Karin, Monika and Schneider, Julia S and Strasoldo-Graffemberg, Theresa and Koch, Nadine and Macke, Lukas and Reiter, Florian P and Lange, Christian M and Wang, Yinghong and De Toni, Enrico N and Gerhard, Markus and Mayerle, Julia and Ricke, Jens and Malfertheiner, Peter},
  title = {Impact of Helicobacter pylori on Immune Checkpoint Inhibition in Hepatocellular Carcinoma: A Multicenter Study},
  journal = {Digestion},
  year = {2025},
  doi = {10.1159/000542847}
}
Kostenlos starten →